1. Home
  2. RMCF vs BCDA Comparison

RMCF vs BCDA Comparison

Compare RMCF & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$0.96

Market Cap

14.9M

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.83

Market Cap

13.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
BCDA
Founded
1981
N/A
Country
United States
United States
Employees
N/A
21
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
13.6M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
RMCF
BCDA
Price
$0.96
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
170.0K
717.1K
Earning Date
06-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$0.78
52 Week High
$2.99
$2.42

Technical Indicators

Market Signals
Indicator
RMCF
BCDA
Relative Strength Index (RSI) 31.03 38.17
Support Level $0.84 $0.81
Resistance Level $1.19 $1.29
Average True Range (ATR) 0.12 0.09
MACD 0.01 -0.03
Stochastic Oscillator 34.86 4.01

Price Performance

Historical Comparison
RMCF
BCDA

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: